Ainos reports 75-case clinical trial progress for Ainos Flora; next-gen device with NVIDIA CUDA targeting Q3/Q4

Ainos, Inc.

Clinical trials for AI Nose-powered Ainos Flora achieved 75 meaningful case results, validating AI algorithm model.
Next-gen Ainos Flora will leverage NVIDIA CUDA for accelerated deep learning; design completion expected Q3, clinical trials Q4.
Second-generation device targets at-home testing for viral infections, expanding beyond bacterial/fungal/STI detection.
Board approved amended bylaws reducing stockholder meeting quorum to one-third and adding advance notice procedures.
STI testing market projected US$256B by 2028; POCT accounts for 31%, presenting opportunity for telehealth-friendly rapid testing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.